Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients

被引:21
|
作者
Herebian, Diran [1 ]
Spiekerkoetter, Ute [1 ]
Lamshoeft, Marc [2 ]
Thimm, Eva [1 ]
Laryea, Maurice [1 ]
Mayatepek, Ertan [1 ]
机构
[1] Univ Dusseldorf, Univ Childrens Hosp, Dept Gen Paediat, D-4000 Dusseldorf, Germany
[2] Univ Dortmund, Inst Environm Res, D-44221 Dortmund, Germany
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2009年 / 877卷 / 14-15期
关键词
NTBC; Tyrosinemia type 1; HPLC-ESI-MS/MS; LTQ-Orbitrap; INHIBITORS;
D O I
10.1016/j.jchromb.2009.03.014
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In this study, we describe a bioanalytical method for quantification of NTBC in plasma of patients with hereditary tyrosinemia type 1 (HT-1) using high-performance liquid chromatography Coupled to tandem mass spectrometry (LC-MS/MS). After protein precipitation with acetonitrile including Mesotrione as internal standard, separation of NTBC was achieved by RP-HPLC. Detection was performed by positive ion electrospray ionization (ESI) in selected reaction monitoring (SRM) mode. NTBC recovery in the developed method was found to be more than 90%. The lower limit Of quantification was calculated to be 0.35 mu M. The intra-day and inter-clay precision of three different quality control samples (measured as RSD%) was less than 10% and 15%, respectively. The standard calibration curves showed good linearity within the range of 2.5-40 mu M and the determined correlation coefficients were r(2) >= 0.995. This presented method is rapid. sensitive, specific and suitable for clinical practice and research. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:1453 / 1459
页数:7
相关论文
共 50 条
  • [1] Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)
    Holme, E
    Lindstedt, S
    JOURNAL OF INHERITED METABOLIC DISEASE, 1998, 21 (05) : 507 - 517
  • [2] The effectiveness of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) as a therapeutic agent for tyrosinemia-I: The US experience
    Scott, CR
    Sniderman, LC
    Smith, CO
    Feldman, K
    PEDIATRIC RESEARCH, 2000, 47 (04) : 168A - 168A
  • [3] CAPILLARY ELECTROPHORESIS FOR THE CONTROL OF THE OPTIMAL DOSE OF NTBC (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) IN SERUM SAMPLES OF HEREDITARY TYROSINEMIA TYPE I PATIENTS
    Cansever, M. Serif
    Zeybek, A. Cigdem Aktuglu
    Erim, F. Bedia
    MOLECULAR GENETICS AND METABOLISM, 2009, 98 (1-2) : 33 - 33
  • [4] Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC)
    Luijerink, MC
    Jacobs, SMM
    van Beurden, EACM
    Koornneef, LP
    Klomp, LWJ
    Berger, R
    van den Berg, IET
    JOURNAL OF HEPATOLOGY, 2003, 39 (06) : 901 - 909
  • [5] Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)
    Raimann, Erna
    Cornejo, Veronica
    Arias, Carolina
    Francisco Cabello, Juan
    Castro, Gabriela
    Fernandez, Eloina
    de la Parra, Alicia
    REVISTA MEDICA DE CHILE, 2012, 140 (02) : 169 - 175
  • [6] Determination of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in plasma by direct injection into a coupled column liquid chromatographic system
    Bielenstein, M
    Astner, L
    Ekberg, S
    JOURNAL OF CHROMATOGRAPHY B, 1999, 730 (02): : 177 - 182
  • [7] Simple and Fast Quantification of Nitisone (NTBC) using Liquid Chromatography-Tandem Mass Spectrometry Method in Plasma of Tyrosinemia Type 1 Patients
    Davit-Spraul, Anne
    Romdhane, Houda
    Poggi-Bach, Josephine
    JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2012, 50 (05) : 446 - 449
  • [8] From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug
    Lock, EA
    Ellis, MK
    Gaskin, P
    Robinson, M
    Auton, TR
    Provan, WM
    Smith, LL
    Prisbylla, MP
    Mutter, LC
    Lee, DL
    JOURNAL OF INHERITED METABOLIC DISEASE, 1998, 21 (05) : 498 - 506
  • [9] TYROSINEMIA TYPE 1: THERAPEUTIC DRUG MONITORING OF NTBC IN PLASMA/SERUM USING LIQUID CHROMATOGRAPHY COUPLED TO TANDEM MASS SPECTROMETRY
    Hercbian, D.
    Thimm, E.
    Mayatepek, E.
    Spiekerkoetter, U.
    MOLECULAR GENETICS AND METABOLISM, 2009, 98 (1-2) : 19 - 19
  • [10] Characterization of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione resistance in pyomelanogenic Pseudomonas aeruginosa DKN343
    Ketelboeter, Laura M.
    Bardy, Sonia L.
    PLOS ONE, 2017, 12 (06):